Auranofin: repurposing an old drug for a golden new age

Roder, Christine and Thomson, Melanie J. 2015, Auranofin: repurposing an old drug for a golden new age, Drugs in R&D, vol. 15, no. 1, pp. 13-20, doi: 10.1007/s40268-015-0083-y.

Attached Files
Name Description MIMEType Size Downloads

Title Auranofin: repurposing an old drug for a golden new age
Author(s) Roder, Christine
Thomson, Melanie J.
Journal name Drugs in R&D
Volume number 15
Issue number 1
Start page 13
End page 20
Total pages 8
Publisher Adis International
Place of publication Auckland, N.Z
Publication date 2015-03
ISSN 1179-6901
Summary Drug discovery, development and registration is an expensive and time-consuming process associated with a high failure rate [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Woodcock and Woosley (Annu Rev Med 59:1-12, 2008)]. Drug 'repurposing' is the identification of new therapeutic purposes for already approved drugs and is more affordable and achievable than novel drug discovery [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013)]. Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)]. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes that are essential for maintaining intracellular levels of reactive oxygen species. Inhibition of these enzymes leads to cellular oxidative stress and intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Fan et al. (Cell Death Dis 5:e1191, 2014), Fiskus et al. (Cancer Res 74:2520-2532, 2014), Marzano et al. (Free Radic Biol Med 42:872-881, 2007)]. Drugs such as auranofin that have already been approved for human use [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)] can be brought into clinical use for other diseases relatively quickly and for a fraction of the cost of new drugs.
Language eng
DOI 10.1007/s40268-015-0083-y
Field of Research 111502 Clinical Pharmacology and Therapeutics
Socio Economic Objective 920204 Evaluation of Health Outcomes
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Springer
Persistent URL http://hdl.handle.net/10536/DRO/DU:30072102

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 124 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 78 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Thu, 09 Apr 2015, 10:45:23 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.